乳腺癌蒽环类化疗相关心脏毒性早期识别及预防的研究进展  

Research progress on early identification and preventive measures of cardiotoxicity induced by anthracycline chemotherapy in breast cancer

作　　者：周彦君 李秋月 胡宇乐 杨浩杰 赵芳[2] 梁涛[1] ZHOU Yanjun;LI Qiuyue;HU Yule;YANG Haojie;ZHAO Fang;LIANG Tao

机构地区：[1]中国医学科学院/北京协和医学院护理学院,北京市100144 [2]中国医学科学院肿瘤医院肿瘤内科

出　　处：《中华护理杂志》2023年第7期816-821,共6页Chinese Journal of Nursing

基　　金：北京协和医学院护理学院院级科研课题(PUMCSON202102)。

摘　　要：蒽环类药物相关心脏毒性是接受化疗的乳腺癌患者生存期死亡的首要原因,不仅在一定程度上限制了药物的临床应用,也对患者的远期预后、生活质量及生命造成了严重威胁。蒽环类药物相关心脏毒性的早期识别和干预可提高患者的生存获益,逆转负性结局。该文对乳腺癌蒽环类药物化疗患者心脏毒性危险因素、评估工具以及预防措施进行综述,旨在改善患者的生活质量,最大程度提高患者的生存获益,为临床进一步探索有效的预防措施提供依据。Anthracycline-induced cardiotoxicity(ACT)is the primary cause of survival death in breast cancer patients receiving chemotherapy,which not only limits the clinical application of drugs to a certain extent,but also poses a serious threat to the long-term prognosis,quality of life and life of patients.Early identification and intervention of ACT can improve the survival benefit of patients and reverse negative outcomes.This article reviews the risk factors,assessment tools and preventive measures of cardiotoxicity in patients with breast cancer undergoing anthracycline chemotherapy,aiming to provide references for clinical nursing care,improve the quality of life of patients and maximize the survival benefit of patients.It also provides a basis for further clinical exploration of effective preventive measures.

关 键 词：乳腺肿瘤 蒽环类药物 化疗 心脏毒性 综述 护理 

分 类 号：R473.73[医药卫生—护理学]